Fast-casual restaurant Dos Toros is one of the latest chains to go cash-free.
Marketing manager Marcus Byrd said that the change saved the team time and that most customers didn’t even notice a difference.
“We found that 85 percent of customers use cards already at Dos Toros,” he said in a Cheddar interview. “And of those 15 percent that use cash, we only found that one percent could not go to Dos Toros.”
The company first went cashless in October and other chains such as Sweetgreen have made similar changes. One recent study finds that nearly two-thirds of smartphone users dole out cash sometimes, they prefer to use cards or mobile payments. Research firm eMarketer credits speed and convenience, safety, and rewards for the change.
Still, going all digital does come with disadvantages. Power outages or WiFi issues mean payments can’t be processed. And the “unbanked” population -- the estimated 7 percent of U.S. households without a bank account are excluded.
Byrd says that the company is focused on bringing in those consumers.
“We’re actually going to come out with an app next year, and we hope that there’s a location that can accept cash and turn that into money on your app or on a gift card, so that everybody can enjoy Dos Toros,” he said.
For the full interview [click here](https://cheddar.com/videos/dos-toros-goes-cashless).
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d